PMID- 15180861
OWN - NLM
STAT- MEDLINE
DCOM- 20040716
LR  - 20171116
IS  - 0007-1048 (Print)
IS  - 0007-1048 (Linking)
VI  - 125
IP  - 6
DP  - 2004 Jun
TI  - Phenotypic and functional characterization of monocyte-derived dendritic cells in 
      chronic lymphocytic leukaemia patients: influence of neoplastic CD19 cells in 
      vivo and in vitro.
PG  - 720-8
AB  - Dendritic cells (DCs) are the most potent antigen-presenting cells and are 
      therefore an attractive option as antigen carriers in vaccination protocols. 
      Chronic lymphocytic leukaemia (CLL) represents a potential good target for these 
      approaches. The present study was designed to investigate the feasibility of 
      generating in vitro fully functional DCs from peripheral blood (PB) monocytes of 
      CLL patients at different phases of the disease. Although functional DCs could be 
      obtained from CLL samples, in patients with active disease the expression of some 
      co-stimulatory molecules appeared to be reduced. In contrast, DCs from CLL 
      patients in remission showed no difference from those of normal controls. 
      Moreover, patients with active disease produced DCs with reduced allostimulatory 
      ability when compared with normal ones, whereas the functional capacities 
      appeared to be restored in CLL DCs from remission patients. To more precisely 
      assess the possible inhibitory effect of CLL cells on DC development, the 
      influence of autologous leukaemic CD19(+) cells on the generation of 
      monocyte-derived CLL DCs in vitro was investigated. The addition of CLL 
      neoplastic cells markedly affected monocyte-derived DC maturation. In conclusion, 
      monocytes from CLL patients with active disease give rise to DCs, which show 
      phenotypic and functional defects that are not observed in remission CLL 
      patients. These results need to be taken into account in the design of DC-based 
      immunotherapeutic approaches in CLL.
FAU - Orsini, Enrica
AU  - Orsini E
AD  - Dipartimento di Biotecnologie Cellulari ed Ematologia, University La Sapienza, 
      Rome, Italy. orsini@bce.uniroma1.it
FAU - Pasquale, Alessia
AU  - Pasquale A
FAU - Maggio, Roberta
AU  - Maggio R
FAU - Calabrese, Elisabetta
AU  - Calabrese E
FAU - Mauro, Francesca Romana
AU  - Mauro FR
FAU - Giammartini, Elena
AU  - Giammartini E
FAU - Guarini, Anna
AU  - Guarini A
FAU - Foa, Robin
AU  - Foa R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Haematol
JT  - British journal of haematology
JID - 0372544
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antibodies, Monoclonal, Murine-Derived)
RN  - 0 (Antibodies, Neoplasm)
RN  - 0 (Antigens, CD19)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Biomarkers)
RN  - 0 (Cancer Vaccines)
RN  - 3A189DH42V (Alemtuzumab)
RN  - 4F4X42SYQ6 (Rituximab)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Alemtuzumab
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Antibodies, Monoclonal, Murine-Derived
MH  - Antibodies, Neoplasm/therapeutic use
MH  - Antigens, CD19/*immunology
MH  - Antineoplastic Agents/therapeutic use
MH  - Biomarkers/analysis
MH  - Cancer Vaccines
MH  - Case-Control Studies
MH  - Clone Cells
MH  - Coculture Techniques
MH  - Dendritic Cells/*immunology
MH  - Female
MH  - Flow Cytometry
MH  - Humans
MH  - Immunotherapy, Adoptive
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/*immunology/therapy
MH  - Male
MH  - Middle Aged
MH  - Rituximab
EDAT- 2004/06/08 05:00
MHDA- 2004/07/17 05:00
CRDT- 2004/06/08 05:00
PHST- 2004/06/08 05:00 [pubmed]
PHST- 2004/07/17 05:00 [medline]
PHST- 2004/06/08 05:00 [entrez]
AID - BJH4971 [pii]
AID - 10.1111/j.1365-2141.2004.04971.x [doi]
PST - ppublish
SO  - Br J Haematol. 2004 Jun;125(6):720-8. doi: 10.1111/j.1365-2141.2004.04971.x.